drugset / Trial / NCT00291356

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

NCT00291356

Phase 2 Completed 45 enrolled GlaxoSmithKline
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.

Timeline

Start
2006-01
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GW869682 Unknown Oral
Subject remogliflozin etabonate Small molecule Oral